RespireRx Pharmaceuticals Inc (fka RSPI)

[striaterminalis]

GFP,

Actually, COR does not have the endocrine patents anymore. These were procured by OLAS pharmaceuticals, who subsequently conducted more experiments in rats to replicate original findings and extend the principle to other hormones. A PR link is attached. Note that the PR describes how ampakiens increase GH and DHEA levels, while reducing levels of CORT. This is significant in two regards. 1) ampakiens induce changes in the levels of GH, DHEA and CORT that are opposite to what occurs during aging. As we age, CORT goes up whle DHEA and GH go down, and this is implicated in many age associated diseases of somatic tissues and CNS, as well as normal aging. Ampakines appear to elevate DHEA and GH, whle reducing CORT. 2) in that there is a link between peripheral GH levels and central BDNF levels, this patent may very well allow them to get in on the neurotrophin angle.

http://biz.yahoo.com/pz/070918/126875.html